Search Results for "dabigatran"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for dabigatran. Results 21 to 28 of 28 total matches.
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
the anticoagulant effect of dabigatran
(Pradaxa); whether PCCs can safely reverse the
anticoagulant effect ...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):31-2 doi:10.58347/tml.2024.1696d | Show Introduction Hide Introduction
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017 (Issue 1531)
)
Dosage Adjustment of Interacting Drug Recommended
Digoxin (increased digoxin concentrations)
Dabigatran ...
The FDA has approved Mavyret (Abbvie) and Vosevi
(Gilead), two new fixed-dose combinations of direct-acting
antiviral (DAA) drugs, for treatment of chronic
hepatitis C virus (HCV) infection caused by any of the
six major HCV genotypes in patients without cirrhosis
or with compensated cirrhosis. Both are approved for
use in treatment-experienced patients. Mavyret is also
approved for treatment-naive patients.
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
or hip replacement. Dabigatran (Pradaxa), a
direct thrombin inhibitor, is approved for such use
only ...
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who have moderately or severely restricted mobility
and other risk factors for VTE. Betrixaban is the
first oral anticoagulant to be approved in the US for
this indication.
Daclatasvir (Daklinza) for HCV Genotype 3 Infection
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015 (Issue 1479)
of these transporters, such as digoxin
(Lanoxin, and others), the anticoagulant dabigatran
(Pradaxa), or statins ...
The FDA has approved daclatasvir (Daklinza – BMS),
an oral direct-acting antiviral drug, for use with
sofosbuvir (Sovaldi) for treatment of chronic hepatitis
C virus (HCV) genotype 3 infection. Daclatasvir is
the first drug approved for this indication that does
not require the addition of interferon or ribavirin. It is
approved in Japan and Europe in combination with
other drugs for treatment of HCV genotypes 1-4.
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
, such as dabigatran (Pradaxa),
could increase serum concentrations of the substrate.5
Elagolix is also a substrate ...
The FDA has approved elagolix (Orilissa – AbbVie),
an oral gonadotropin-releasing hormone (GnRH)
antagonist, for management of moderate to severe
pain associated with endometriosis.
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
are at increased risk for
muscular adverse effects.10
In patients taking dabigatran etexilate (Pradaxa ...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Drugs for Hepatitis C Virus Infection
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
., statins, cyclosporine, dabigatran,
digoxin).
Glecaprevir and pibrentasvir are substrates of P-gp ...
About 2.5 million persons in the US had hepatitis C
between 2017 and 2020. Guidelines from the American
Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society of America (IDSA)
on management of hepatitis C virus (HCV) infection
were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74 doi:10.58347/tml.2024.1714a | Show Introduction Hide Introduction
Comparison Table: Some Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
increase the risk of major hemorrhage
in patients taking dabigatran etexilate (Pradaxa); mechanism ...
View the Comparison Table: Some Lipid-Lowering Drugs